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Objective. Adiponectin is known to be decreased in insulin resistance (IR) and metabolic syndrome (MS) which can be present
in patients with type 1 diabetes mellitus (T1DM). The aim of this study was to evaluate the relationship between adiponectin
level, MS, and insulin sensitivity in T1DM. Research Design and Methods. The study included 77 T1DM patients divided into two
groups based on the total plasma adiponectin median value. Insulin sensitivity was calculated with the equation for eGDR, and
MS was defined according to International Diabetes Federation criteria. Results. Patients with higher adiponectin level (𝑛 = 39)
had significantly lower waist circumference (𝑃 < 0.002), fasting venous glucose levels (𝑃 < 0.001), higher HDL3-cholesterol
(𝑃 = 0.011), and eGDR (𝑃 = 0.003) in comparison to the group with lower adiponectin who showed higher prevalence of MS
(𝑃 = 0.045). eGDR increased for 1.09mg/kg−1min−1 by each increase of 1 𝜇g/mL total fasting plasma adiponectin (𝑃 = 0.003).
In the logistic regression model, adiponectin was inversely associated with the presence of MS (𝑃 = 0.014). Conclusion. Higher
adiponectin concentration is associated with lower prevalence of MS in T1DM. Whether higher adiponectin concentration has a
protective role in the development of the MS in T1DM needs to be clarified in future follow-up studies.
1. Introduction
White adipose tissue is a major site of energy storage and is
important for energy homeostasis. It has been increasingly
recognised as an important endocrine organ that secretes
a number of biologically active “adipokines” like tumor
necrosis factor-𝛼, plasminogen activator inhibitor-1, leptin,
resistin, angiotensinogen, and adiponectin [1]. Some of these
adipokines are associated with obesity-related conditions.
Adiponectin has attracted much attention because of its
antidiabetic and antiatherogenic effect, and it might become
a novel therapeutic tool for type 2 diabetes mellitus (T2DM)
and metabolic syndrome (MS) [2, 3]. According to several
studies, plasma concentration of adiponectin is reduced in
human obesity, particularly visceral, and negatively corre-
lated with insulin resistance (IR) [4, 5]. Additionally, hypoad-
iponectinemia is independently associated with the MS,
surrogate marker of IR, and significantly related to T2DM
development [5–7]. MS represents an important risk factor
for mortality and micro- and macrovascular complications
development both in patients with type 1 diabetes mellitus
(T1DM) and T2DM [8]. Adiponectin was found to accumu-
late in damaged vascular walls and beneficially modulate the
endothelial inflammatory response to vascular injury as it
possesses antiinflammatory and antiatherogenic properties
[9]. Consequently, normal adiponectin concentrations or
even induction of elevated concentrations are considered to
be beneficial. However, increased adiponectin concentrations
have been found to be associatedwith an increased cardiovas-
cular mortality in T1DM [10, 11], but in cross-sectional data,
the elevation in adiponectin levels has been hypothesised
as a compensatory response in T1DM patients who have
microvascular complications [10]. In addition, there are a
growing number of patients with T1DM and MS who appear
to be at increased risk of cardiovascular mortality and devel-
opment of diabetes related complications, a greater need for
higher insulin doses, and multifactorial intervention, thus,
more aggressive treatment [12, 13]. Therefore, the purpose
of this study was (1) to determine the relationship between
total plasma adiponectin concentrations and parameters
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associated with the MS: body mass index (BMI), waist
circumference, lipid profile, blood pressure levels, fasting
glucose levels, and insulin sensitivity, (2) to determine the
relationship between adiponectin concentrations and MS
prevalence, and (3) to evaluate the possible pathophysiologi-
cal role of adiponectin in MS development in T1DM patients
defined according to International Diabetes Federation (IDF)
criteria.
2. Subjects, Materials, and Methods
This cross-sectional study was undertaken at the University
Clinic for Diabetes, Endocrinology, and Metabolic Diseases
Vuk Vrhovac, Zagreb, Croatia. The study population con-
sisted of 77 T1DM patients coming for their comprehensive
annual review with following characteristics: age of 18–65
years, minimumduration of type 1 diabetes of 1 year, nomed-
ical history of cardiovascular diseases or electrocardiogram
(ECG) evidence of ischemic heart disease, absence of any sys-
temic disease, and absence of any infections in the previous
month. T1DMwas defined as age at onset of diabetes younger
than 35 years, positive autoantibodies, and time to definite
insulin therapy less than a year. Patients were excluded from
the study if they had taken any of the following: thyroid
hormone therapy, medications that might affect glucose
metabolism and insulin sensitivity such as glucocorticoids,
oral contraceptives, and patients taking oral glucose-lowering
medication. They could be using antihypertensive or lipid
lowering drugs (i.e., statins: atorvastatin and simvastatin).
Acute and chronic inflammation was excluded on the basis of
medical history, physical examination, and routine laboratory
tests, including measurement of temperature and urinalysis.
All subjects were studied in the morning between
08:00 am and 09:30 am after an overnight fast. Waist cir-
cumference was measured on bare skin as the narrowest
circumference between the 10th rib and the iliac crest with
tailor meter. Weight was measured by the physician using a
balanced-beam scale with light clothing without shoes and
expressed in kilograms (kg). Height was measured using
a wall-mounted stadiometer and expressed in centimetres
(cm). Body mass index (BMI) was calculated as weight in
kilograms divided by the square of height in meters (kg/m2).
Blood pressure was measured in the sitting position with
a mercury sphygmomanometer after a resting period of 10
minutes and expressed in mmHg. Fasting venous blood
samples were collected for the determination of biochemistry
panel, lipid profile status, HbA1c, liver biochemistry, and
adiponectin. HbA1c was measured spectrophotometrically
by turbidimetric immunoinhibition (Olympus AU600, Beck-
man Coulter, USA). Glucose, cholesterol, and triglycerides
in serum were measured by an enzymatic colorimetric
method. Total fasting adiponectin was measured using
BioVendor’s Human ELISA (sandwich) commercial kit for
research use only. Insulin sensitivity was calculated using
the equation derived from euglycemic-hyperinsulinemic
clamp studies estimated glucose disposal rate (eGDR):
24.31–12.2𝑋(WHR)–3.29𝑋(AHT)−0.57𝑋(HbA1c), where the
units aremg/kg−1min−1,WHR indicates thewaist to hip ratio,
AHT indicates blood pressure and is expressed as 0—no, 1—
yes.Those on blood pressure medications or with blood pres-
sure >140/90mmHg were considered to have hypertension
[14]. This equation was derived from a substudy of 24 EDC
(Epidemiology of Diabetes Complications) participants (12
men and 12 women drawn from low, middle, and high age-
specific tertiles of insulin resistance risk factors in order to
represent the spectrum of insulin resistance) who underwent
euglycemic-hyperinsulinemic clamp studies [15]. It should be
emphasized that lower eGDR levels indicate greater insulin
resistance. According to the IDF guidelines, participants were
defined as having MS if they had central obesity defined as
waist circumference with ethnicity specific values (>80 cm in
female and 94Cm in male population) plus any two of the
following four factors: raised TG concentration: >150mg/dL
(1.7mmol/L), specific treatment for this lipid abnormality,
reduced HDL cholesterol: <40mg/dL (1.03mmol/L) in males
and <50mg/dL (1.29mmol/L) in females, specific treatment
for this lipid abnormality, raised blood pressure: systolic BP
>130 or diastolic BP >85mmHg, treatment of previously
diagnosedhypertension, raised fasting plasma glucose (FPG):
>100mg/dL (5.6mmol/L), or previously diagnosed type 2
diabetes [16].
The study protocol complies with the Declaration of
Helsinki as well as with local institutional guidelines and was
approved by the local ethics committees. Written informed
consent was obtained from all participants.
Baseline data were reported using descriptive statistics.
Normality of distribution for continuous variables was anal-
ysed using Shapiro-Wilk test. Normally distributed variables
were described with mean and standard deviation (SD),
while variables that were not normally distributed were
described withmedian, minimum, andmaximum.The nom-
inal variables were reported with absolute numbers and/or
percentages. Differences between groups were examined,
depending on the nature of the data, using parametric (𝑡-
test) or nonparametric tests (Mann-Whitney). Correlations
between parameters of adiponectin with anthropometric
and metabolic variables were determined using Pearson’s or
Spearman’s correlation coefficient. The association between
total fasting adiponectin concentrations and eGDR value
was further evaluated in univariate linear regression, and in
order to evaluate the association of total fasting adiponectin
concentration with MS presence, we constructed multivari-
able binary logistic regression models to assess whether cir-
culating total adiponectin concentration was independently
associated with MS. Adjustments were performed for age,
gender, disease duration, and the use of statins since they are
shown to affect adiponectin secretion [17]. Level of statistical
significance was chosen to be 0.05. Statistical analysis was
performed by Statistical Package for the Social Sciences
(SPSS) ver. 17.0 for Windows.
3. Results
The characteristics of the study subjects are listed in Table 1.
The average age was approximately 46 years, median BMI
was 25 kg/m2, and 61% of patients were males with median
diabetes duration of 21 years. Forty-five (58.4%) were using
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Table 1: Demographic, anthropometric, and clinical characteristics
of the 77 patients with type 1 diabetes.
Variable Mean/median SD/range
Age (years) 45.66 11.87
Gender (m/f) 47/30
Duration of diabetes (years) 21.0 1.0–47.0
Weight (kg) 76 52–112
BMI (kg/m2) 25 18–36
Waist circumference (cm) 85.6 11.8
HbA1c (%) 7.3 5.4–12.2
SBP (mmHg) 130 100–165
DBP (mmHg) 80 60–110
eGDR (mg/kg−1 min−1) 6.77 3.78–11.65
LDL cholesterol (mmol/L) 2.95 1.49–5.32
Total HDL cholesterol (mmol/L) 1.56 0.78–3.83
HDL2 cholesterol (mmol/L) 0.44 0.2–2.8
HDL3 cholesterol (mmol/L) 1.13 0.39–2.28
Triglycerides (mmol/L) 1.19 0.61
AST (U/L) 23.5 13–57
ALT (U/L) 24 12–95
GGT (U/L) 20 10–92
ALP (U/L) 76 18–155
Adiponectin (𝜇g/mL) 14.10 3.4–31.4
ALP: alkaline phosphatase, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, GGT: 𝛾-glutamyltransferase, BMI: bodymass index, DBP:
diastolic blood pressure, HbA1c: glycated hemoglobin, eGDR: estimated
glucose disposal rate, and SPB: systolic blood pressure.
antihypertensive therapy and 33 (42.9%) hypolipedemic
medications. Patients were divided according to the median
adiponectin value (14.1 (3.4–31.4) 𝜇g/mL). The group of
patients (𝑛 = 38) with lower adiponectin concentrations
(<14.1 𝜇g/mL) had significantly shorter disease duration,
higher weight, BMI, waist circumference, GGT, and fasting
venous glucose levels (8.45 versus 6.80mmol/L, 𝑃 < 0.001),
while lower HDL3-cholesterol and eGDR compared to the
group (𝑛 = 39) with higher adiponectin concentrations
(>14.1 𝜇g/mL) (Table 2). No significant difference was found
in the use of antihypertensive (60.5% versus 56.4%) or
hypolipedemic (39.5% versus 46.2%) therapy between the
two groups. Associations of adiponectin concentrations with
anthropometric and metabolic variables are presented in
Table 3. Disease duration, total HDL and HDL3 cholesterol
showed significantly positive correlation with adiponectin
concentrations; weight, BMI, waist circumference, systolic
blood pressure, and eGDR showed significantly negative cor-
relation with adiponectin concentrations. Between all study
patients, 26 (33.8%) met the metabolic syndrome criteria.
In linear regression model, the unadjusted eGDR
increased for 1.09mg/kg−1min−1 by each increase of 1 𝜇g/mL
total plasma adiponectin (CI (1.03–1.16), 𝑃 = 0.003). In the
multivariate binary logistic regression, total fasting plasma
adiponectin was inversely associated with presence of MS
after adjustment for age, sex, disease duration, and the statin
use (Table 4). The other variables included in the final model
were not shown to be significant predictors of the MS
presence (age OR = 0.977, 𝑃 = 0.459; gender OR = 0.639,
𝑃 = 0.418; disease duration OR = 1.022, 𝑃 = 0.452; and the
use of statins OR = 0.886, 𝑃 = 0.140).
4. Discussion
Although pathophysiology of T1DM is defined with an
autoimmune destruction of pancreatic 𝛽 cells, increased IR
has an important role in the development of so called “double
diabetes” and greater risk for micro- and macrovascular
complications [18]. MS and increased IR can be found in
about 30%–40 % of T1DM patients depending on the used
MS definition [19–21]. The association of lower adiponectin
concentrations with the risk of MS development was previ-
ously shown in both healthy population and T2DM patients
[5–7, 22].
Our results show that patients with higher plasma
adiponectin concentrations had significantly lower BMI and
waist circumference and higher HDL 3 cholesterol.The levels
of systolic blood pressure, fasting plasma glucose, and triglyc-
eride were also lower although they did not reach statistical
significance. Additionally, the group with higher plasma
adiponectin showed higher eGDR levels indicating higher
insulin sensitivity which is in accordance with Pereira et al.
(2012) [23] who reported that both total and high molecular
weight (HMW) adiponectin positively correlate with insulin
sensitivity assessed by hyperinsulinemic-euglycemic clamp
in T1DM patients. Pham et al. (2013) [24] also investigated
the association of total plasma adiponectin, anthropometric
and metabolic parameters and found an inverse association
of total plasma adiponectin and fasting glucose levels as well
as BMI. About 35%–40% of the observed patient population
met MS criteria, which is in accordance with the literature
data [12, 18]. In the multivariate logistic regression after
adjustment for age, gender, disease duration, and the use of
statins, adiponectin concentration was significantly inversely
associated with the prevalence of the MS. Those data sug-
gest that higher adiponectin concentrations might play an
important protective role in the development of MS in T1DM
patients.
Adiponectin has been shown to have insulin-sensitizing
effects through activation of AMPK in the peripheral tissues
[25]. These effects include stimulation of fatty acid oxidation
and glucose uptake in skeletal muscle and suppression of glu-
cose production in the liver [26]. Several experimental studies
suggested that administration of adiponectin ameliorates IR
in lipoatrophic and T2DM while it decreases plasma glucose
levels in healthymice [26, 27]. For those reasons, adiponectin
is considered to be one of the major insulin-sensitizing
hormones strongly associated with IR related disorders.
Additionally, regarding the glucose metabolism, Berg et al.
(2001) have shown that the administration of adiponectin
lowers circulating glucose levels without stimulating insulin
secretion in both healthy and diabetic mice [28], and the
data from two independent studies performed by Kriketos
et al. (2004) as well as Kim et al. (2007) show that exercise
induced increased insulin sensitivity in humans could be due
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Table 2: Clinical and metabolic characteristics of patients depending on adiponectin concentrations.
Variable Adiponectin < 14.10𝜇g/mL Adiponectin > 14.10𝜇g/mL 𝑃
Age (years) 43.8 ± 13.72 46.26 ± 9.79 NS
Gender (m/f) 31/7 16/23 NS
Duration of diabetes (years) 17.5 (1–41) 25 (2–47) 0.015
Weight (kg) 83 (52–112) 68 (54–103) <0.001
BMI (kg/m2) 26 (18–33) 24 (20–36) 0.027
Waist circumference (cm) 90.5 ± 10.4 80.9 ± 11.3 <0.002
HbA1c (%) 7.3 (5.41–11.1) 7.2 (5.4–12.2) NS
SBP (mmHg) 130 (110–160) 125 (100–165) NS
DBP (mmHg) 80 (60–110) 80 (60–100) NS
eGDR (mg/kg−1 min−1) 6.06 (3.79–10.01) 7.67 (3.78–11.65) 0.003
LDL cholesterol (mmol/L) 2.79 (1.83–5.20) 2.74 (1.49–5.32) NS
Total HDL cholesterol (mmol/L) 1.46 (0.83–3.83) 1.66 (0.78–2.62) NS
HDL2 cholesterol (mmol/L) 0.43 (0.20–2.80) 0.44 (0.21–1.05) NS
HDL3 cholesterol (mmol/L) 1.06 (0.56–1.53) 1.23 (0.39–2.28) 0.011
Triglycerides (mmol/L) 1.27 ± 0.64 1.11 ± 0.58 NS
AST (U/L) 24 (15–42) 22 (13–57) NS
ALT (U/L) 27.5 (12–91) 22 (12–95) NS
GGT (U/L) 25 (13–92) 16 (10–59) 0.042
ALP (U/L) 77 (18–155) 75 (36–140) NS
MS presence (𝑛, %) 17 (44.7%) 9 (23.1%) 0.045
ALP: alkaline phosphatase, ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: 𝛾-glutamyltransferase, BMI: body mass index, DBP:
diastolic blood pressure, HbA1c: glycated hemoglobin, eGDR: estimated glucose disposal rate, and SPB: systolic blood pressure.
Table 3: Correlation analysis of adiponectin concentrations with
metabolic and anthropometric variables.
Variable
Duration of diabetes (years) 0.370∗
Weight (kg) −0.502∗
BMI (kg/m2) −0.367∗
Waist circumference (cm) −0.512∗
HbA1c (%) 0.076
SBP (mmHg) −0.238∗
DBP (mmHg) −0.149
eGDR (mg/kg−1 min−1) 0.332∗
LDL cholesterol (mmol/L) −0.143
Total HDL cholesterol (mmol/L) 0.332∗
HDL2 cholesterol (mmol/L) 0.049
HDL3 cholesterol (mmol/L) 0.222∗
Triglycerides (mmol/L) −0.129
AST (U/L) −0.062
ALT (U/L) −0.107
GGT (U/L) −0.199
ALP (U/L) −0.34
∗
𝑃 < 0.05.
ALP: alkaline phosphatase, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, GGT: 𝛾-glutamyltransferase, BMI: bodymass index, DBP:
diastolic blood pressure, HbA1c: glycated hemoglobin, eGDR: estimated
glucose disposal rate, and SPB: systolic blood pressure.
to elevation in total plasma adiponectin concentration in
humans [29, 30].
Table 4: Logistic regression analysis of adiponectin concentrations
and diabetes duration with development of metabolic syndrome in
type 1 diabetic patients according to the IDF criteria.
Independent variable Model A Model B Model C
(a) Adiponectin 0.91(0.84–0.98)∗
0.89
(0.82–0.97)∗
0.89
(0.81–0.97)∗
Data are OR (95% CI) from separate models. Model A crude; model B
adjusted for age and sex, model C adjusted for age, sex, duration of diabetes,
and the use of statins.
∗
𝑃 < 0.05.
Moreover, our finding of lower LDL cholesterol andTG as
well as higher total HDL, HDL2, andHDL3 cholesterol in the
group with higher plasma adiponectin is in accordance with
a growing body of literature data suggesting that adiponectin
has a direct effect on the regulation of lipid metabolism.
Decreased adiponectin concentrations have been linked to
higher LDL cholesterol and TG concentrations probably due
to adiponectin directly affecting lipoprotein lipase [31, 32].
Data from two large cross-sectional studies indicate that
circulating adiponectin concentrations are negatively corre-
lated with triglyceride concentrations and strongly positively
correlated with plasma HDL concentrations [32, 33]. There
is even an assumption based on several study reports that
treatment with some of the most used lipid lowering drugs
such as statins and fibrates increases plasma adiponectin
concentration which might contribute to their beneficial
effect in LDL and triglyceride lowering effect [34]. The
LDL cholesterol particle is the major cholesterol transporter
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shown to be a strong independent risk factor for atheroscle-
rotic events associated with MS [35]. Regarding HDL choles-
terol and the process of atherogenesis, it has been shown
that both quantitative and qualitative particle alterations
play an important role [36]. In particular, circulating HDL2
cholesterol was found to protect from atherosclerosis [37,
38], while we previously observed that HDL3 cholesterol
might protect from progression of renal disease in type 1
diabetes [38]. That might be of particular importance in this
population as T1DM represents a chronic condition with an
increased cardiovascular mortality [10, 11]. Beyond observed,
adiponectin might exert a protective effect on atherogenesis
by preventing endothelial damage and decreasing blood
pressure levels.
There are several studies suggesting the inverse correla-
tion of circulating adiponectin concentrations and elevated
arterial blood pressure levels in healthy subjects as well as
in diabetic population which is also in concordance with
our results [39, 40]. It has recently been reenforced by a
5-year prospective study by Chow et al. (2007) who found
hypoadiponectinemia to be a good predictor of hypertension
development even after adjustment for risk factors such as
BMI, sex, and age [41]. The inverse correlation between
adiponectin concentration and waist circumference was pre-
viously described in several studies on MS [8, 13], that
is, intra-abdominal fat mass was found to influence the
concentration of circulating adiponectin more than subcu-
taneous fat. Despite whether hypoadiponectinemia is a cause
or a consequence of intraabdominal obesity has not been fully
addressed yet, so the significantly lower waist circumference
and BMI in our group of patients with higher adiponectin
concentrations might possibly be explained with an indepen-
dent adiponectin effect on weight loss. As suggested by Frue-
bis et al. (2001), adiponectin administration induces weight
loss without decreasing food intake in mice consuming a
high-fat high-sucrose diet [42].
Additionally, in agreement with adiponectin modulat-
ing liver function previosly mentioned, we also found a
negative correlation between plasma adiponectin concentra-
tions and hepatic biomarkers, that is, aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), 𝛾-glutamyl-
transferase (GGT), and alkaline phosphatase (ALP). This
is with accordance with the results of Lo´pez-Bermejo et
al. (2004) who reported that adiponectin concentrations
were associated with plasma concentrations of various liver
function tests in healthy humans suggesting that adiponectin
deficiency is an important risk factor for the development of
fatty liver, steatohepatitis, and other forms of liver injury [43].
The present study has a number of potential limitations.
First, our study was cross-sectional, which limited our ability
to infer a causal relation between adiponectin concentrations
and development of MS in T1DM. Second, we measured
insulin sensitivity using clinical parameters with eGDR and
did not have access to direct, detailed measures of insulin
resistance using euglycemic-hyperinsulinemic clamp test.
Third, our analyses were based on a single measurement of
total fasting adiponectin that may not reflect the relation over
time.
In conclusion, our results highlight the importance of
the relationship between adiponectin, IR, and the presence
of the MS in T1DM. Whether adiponectin is a marker of
MS as well as all components of MS according to the IDF
criteria in T1DM patients and whether higher adiponectin
concentrations have a protective role in the development of
the MS in T1DM need to be clarified in future follow-up
studies.
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